{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:24:03Z","timestamp":1791563043612,"version":"4.3.4"},"reference-count":27,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":691,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.jtct.2021.04.016","type":"journal-article","created":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T14:18:55Z","timestamp":1619446735000},"page":"590.e1-590.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +\/- Plerixafor versus Granulocyte Colony-Stimulating Factor +\/- Plerixafor in the Lenalidomide Era"],"prefix":"10.1016","volume":"27","author":[{"given":"Andrew","family":"Johnsrud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Ladha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Muffly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parveen","family":"Shiraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Osgood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith A.","family":"Shizuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Kai","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Lowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew R.","family":"Rezvani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Everett H.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Negrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Miklos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surbhi","family":"Sidana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2021.04.016_bib0001","article-title":"Rapidly changing myeloma epidemiology in the general population: increased incidence, older patients, and longer survival [e-pub ahead of print]","author":"Turesson","year":"2021","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jtct.2021.04.016_bib0002","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood-2014-10-609461","article-title":"Future distribution of multiple myeloma in the United States by sex, age, and race\/ethnicity","volume":"125","author":"Rosenberg","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.04.016_bib0003","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41409-018-0264-8","article-title":"Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement","volume":"54","author":"Gonsalves","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.04.016_bib0004","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/jamaoncol.2017.4600","article-title":"Autologous transplantation for newly diagnosed multiple myeloma in the era of novel agent induction: a systematic review and meta-analysis","volume":"4","author":"Dhakal","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtct.2021.04.016_bib0005","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2021.04.016_bib0006","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2021.04.016_bib0007","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1007\/s12032-011-0029-3","article-title":"Autologous hematopoietic stem cell transplantation in multiple myeloma and lymphoma: an analysis of factors influencing stem cell collection and hematological recovery","volume":"29","author":"Ungerstedt","year":"2012","journal-title":"Med Oncol"},{"key":"10.1016\/j.jtct.2021.04.016_bib0008","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41408-019-0205-9","article-title":"Current status of autologous stem cell transplantation for multiple myeloma","volume":"9","author":"Al Hamed","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jtct.2021.04.016_bib0009","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.bbmt.2013.10.013","article-title":"Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations","volume":"20","author":"Giralt","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.04.016_bib0010","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/bmt.2015.23","article-title":"G-CSF plus preemptive plerixafor vs hyperfractionated CY plus G-CSF for autologous stem cell mobilization in multiple myeloma: effectiveness, safety and cost analysis","volume":"50","author":"Antar","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.04.016_bib0011","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/bmt.2008.369","article-title":"Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma","volume":"43","author":"Gertz","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.04.016_bib0012","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12885-019-5285-1","article-title":"Optimal chemo-mobilization for the collection of peripheral blood stem cells in patients with multiple myeloma","volume":"19","author":"Song","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jtct.2021.04.016_bib0013","doi-asserted-by":"crossref","first-page":"384","DOI":"10.3816\/CLM.2006.n.014","article-title":"Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma","volume":"6","author":"Dingli","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.jtct.2021.04.016_bib0014","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1038\/bmt.2015.190","article-title":"Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation","volume":"50","author":"Uy","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.04.016_bib0015","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.bbmt.2017.10.008","article-title":"Chemotherapy-based stem cell mobilization does not result in significant paraprotein reduction in myeloma patients in the era of novel induction regimens","volume":"24","author":"Oyekunle","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.04.016_bib0016","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1182\/blood-2008-08-174946","article-title":"Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma","volume":"113","author":"DiPersio","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.04.016_bib0017","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/s41409-020-0940-3","article-title":"Cost and efficacy of peripheral stem cell mobilization strategies in multiple myeloma","volume":"55","author":"Van de Wyngaert","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.04.016_bib0018","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/bmt.2015.322","article-title":"Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study","volume":"51","author":"Afifi","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.04.016_bib0019","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/jca.21280","article-title":"Peripheral blood stem cell mobilization in multiple myeloma patients treated in the novel therapy era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF","volume":"28","author":"Chaudhary","year":"2013","journal-title":"J Clin Apher"},{"key":"10.1016\/j.jtct.2021.04.016_bib0020","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.jcyt.2015.09.002","article-title":"Hematopoietic progenitor cell mobilization with \"just-in-time\" plerixafor approach is a cost-effective alternative to routine plerixafor use","volume":"17","author":"Veltri","year":"2015","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jtct.2021.04.016_bib0021","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.bbmt.2019.11.024","article-title":"Impact of plerixafor use at different peripheral blood CD34+ thresholds on autologous stem cell collection in patients with multiple myeloma","volume":"26","author":"Shah","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.04.016_bib0022","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.bbmt.2010.06.021","article-title":"Chemomobilization with etoposide is highly effective in patients with multiple myeloma and overcomes the effects of age and prior therapy","volume":"17","author":"Wood","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.04.016_bib0023","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/bmt.2010.170","article-title":"Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization","volume":"46","author":"Costa","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2021.04.016_bib0024","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1038\/sj.leu.2404801","article-title":"Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma","volume":"21","author":"Kumar","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2021.04.016_bib0025","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1038\/bmt.2012.60","article-title":"Growth factor plus preemptive (\u201cjust-in-time\u201d) plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure","volume":"47","author":"Costa","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"suppl_1","key":"10.1016\/j.jtct.2021.04.016_bib0026","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1182\/blood-2019-127523","article-title":"Rapid and robust mobilization of CD34+ HSCs without G-CSF following administration of Mgta-145 alone or in combination with plerixafor","volume":"134","author":"DiPersio","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2021.04.016_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2017.11.003","article-title":"Rapid mobilization reveals a highly engraftable hematopoietic stem cell","volume":"172","author":"Hoggatt","year":"2018","journal-title":"Cell"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636721008630?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636721008630?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T02:59:33Z","timestamp":1763002773000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636721008630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S2666636721008630"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2021.04.016","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +\/- Plerixafor versus Granulocyte Colony-Stimulating Factor +\/- Plerixafor in the Lenalidomide Era","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2021.04.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}